DNA Hydrogel-Based Biosensors for Circulating Tumor Cell and Extracellular Vesicle Detection: An Analytical Chemistry Perspective on Clinical Translation.
DNA hydrogel biosensors show programmability for liquid biopsy but require standardization before clinical implementation.
Liquid biopsy enables noninvasive cancer detection through circulating tumor cells (CTCs) and extracellular vesicles (EVs), yet current technologies face challenges in sensitivity, specificity, and clinical scalability that limit their translation. Despite remarkable programmability and multifunctional integration, DNA hydrogel biosensors require rigorous inter-laboratory reproducibility studies, head-to-head comparisons with FDA-cleared reference methods, and standardized analytical reporting before clinical adoption can be recommended.
What the study was
- Study design
- Literature review
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Critical reviews in analytical chemistry
Why it surfaced
Matched topic(s): Early cancer detection. Study design: Literature review. Score 4/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.